Sonnet Deferred Long Term Liab from 2010 to 2024
| SONN Stock | USD 2.98 0.09 3.11% |
Deferred Long Term Liabilities | First Reported 2013-12-31 | Previous Quarter 102.3 K | Current Value 102.3 K | Quarterly Volatility 1.2 M |
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 5.12. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
Sonnet | Deferred Long Term Liab |
Latest Sonnet Biotherapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Sonnet Biotherapeutics Holdings over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Sonnet Biotherapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Sonnet Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 2,877,698 | |
| Geometric Mean | 2,426,251 | |
| Coefficient Of Variation | 30.74 | |
| Mean Deviation | 536,719 | |
| Median | 2,935,737 | |
| Standard Deviation | 884,513 | |
| Sample Variance | 782.4B | |
| Range | 3.4M | |
| R-Value | 0.14 | |
| Mean Square Error | 825.9B | |
| R-Squared | 0.02 | |
| Significance | 0.62 | |
| Slope | 27,814 | |
| Total Sum of Squares | 11T |
Sonnet Deferred Long Term Liab History
About Sonnet Biotherapeutics Financial Statements
Sonnet Biotherapeutics investors utilize fundamental indicators, such as Deferred Long Term Liab, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 3.2 M | 2.1 M |
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.